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To describe 12 yr experience of molecular genetic diagnosis of Spinal Muscular 
Atrophy (SMA) in 460 cases of Turkish patients. 
Materials & Methods
A retrospective analysis was performed on data from 460 cases, referred to 
Medical Genetics Laboratory, Ege University’s Hospital, Izmir, Turkey, pre-
diagnosed as SMA or with family history of SMA between 2003 and 2014. 
The PCR-restriction fragment length polymorphism (RFLP) and the Multiplex 
ligation–dependent probe amplification (MLPA) analysis were performed to 
detect the survival motor neuron (SMN)1 deletions and to estimate SMN1 and 
SMN2 gene copy numbers.
Results
Using PCR-RFLP test, 159 of 324 postnatal and 18 of 77 prenatal cases 
were detected to have SMN1 deletions. From positive samples, 88.13% had 
a homozygous deletion in both exon 7 and exon 8 of SMN1. Using MLPA, 
54.5% of families revealed heterozygous deletions of SMN1, and 2 or 3 copies 
of SMN2, suggesting a healthy SMA carrier. Among patients referred for SMA 
testing, the annual percentage of patients diagnosed as SMA has decreased 
gradually from 90.62% (2003) down to 20.83% (2014).  
Conclusion
Although PCR-RFLP method is a reliable test for SMA screening, MLPA is 
a necessary additional test and provide relevant data for genetic counseling of 
families having previously affected child. The gradual decrease in the percentage 
of patients molecularly diagnosed as SMA shows that clinicians have begun to 
use genetic tests in the differential diagnosis of muscular atrophies. Cost and 
availability of these genetic tests has greatly attributed to their use.
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Introduction
Spinal muscular atrophy (SMA) is an autosomal  recessive inherited  neuromuscular 
disease.  The SMA incidence is 1 in 10.000 live birth, and a carrier frequency of 
1/40-60 (1). SMA ranked second among inherited neuromuscular diseases within 
the Caucasian led to infant mortality (2). SMA is divided into four main categories 
according to the onset of the disease and the severity of the symptoms as follows. 
The Werding-Hoffman disease (type I), SMA type II, Kugelberg-Welander disease 
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AGACTATCAACTTAATTTCTGATCA - 3´ and a 
reverse 5´- CCTTCCTTCTTTTTGATTTTGTCT 
-3´primer for exon 7 and forward 
5´-G T A A T A A C C A A A T G C A A T G T G A A -3´ 
and reverse 5´-CTACAACACCCTTCTCACAG -3´ 
primer for exon 8. An acquired 187 and 189 bp PCR 
product of exon 7 and 8, was digested with DraI and 
DdeI restriction enzymes, respectively, according to 
manufacturer’s protocol. The products were visualized 
by electrophoresis on 4% agarose gel.
Multiplex ligation–dependent probe amplification 
(MLPA) analysis 
Estimation of SMN1 and SMN2 gene copy numbers 
on 5q13 locus was investigated by MLPA analysis. 
All MLPA steps were performed according to the 
manufacturers’ protocol of the SALSA MLPA kit 
(MRC-Hollyland, Netherlands). 
Data analysis was done using ABI-3130 genetic 
analyzer (Applied Biosystems, California, USA), and 




From 324 postnatal samples, 159 cases (49.07%) had 
SMN1 deletions by PCR-RFLP test. From 159 deletion 
positive cases, 140 (88%) had deletion in both exon 
7 and exon 8, remaining 19 (12 %) had only exon 7 
deletion (Table 1). Types of the disease in patients with 
either exon 7 deletion or exons 7 - 8 deletions are given 
in Table 1.
From 2003 to 2014, the rates of postnatal patients 
detected with homozygous deletion have gradually 
decreased. While this rate was 90.62% in 2003, it was 
20.83 % in 2014. During the period of 12 years, the 
average rate of patients had homozygous deletion with 
PCR-RFLP test was 49.04%. 63.82% of postnatal SMA 
patients had family history of SMA. 
SMN1 deletion was shown in 18 (23.38%) samples 
from 77 prenatal cases carrying SMA type I risk. 
Among affected fetuses, sixteen (88.89%) fetuses had 
homozygous deletion in both exon 7 and exon 8 and 
only 2 (11.11%) fetuses had homozygous deletion in 
exon 7 of SMN1 gen.  All families having prenatal test 
(type III), and Adult type (type IV) (3). The survival 
motor neuron (SMN) gene located in 5q13 region is the 
responsible gene of SMA. Two copies of SMN gene are 
located on human chromosome 5q13, telomeric (SMN1) 
and centromeric (SMN2) copy. Mutation or deletion of 
exon 7 of the SMN1 gene is the main reason of SMA 
disease. Homozygous absence of SMN2 detected in 
4.5% of healthy population suggests that the SMN2 
gene is not SMA responsible gene directly, but the 
increased number of SMN2 copies can modify disease 
manifestations (4).
The purpose of this study was to present the results of 
postnatal and prenatal molecular genetic analysis of 460 
cases referred to our medical genetics laboratory over a 
12 yr period, to perform RFLP and MLPA analysis. The 
results of this study can improve genetic counselling 
of incurable SMA disease and prevent recurrence in 
families with SMA history in Turkey.
Materials & Methods
Patients
Data from 460 cases referred to Medical Genetics 
Laboratory, Ege University’s Hospital, Izmir, Turkey 
from January 1st, 2003 to December 31th, 2014, for 
molecular genetic analysis of SMA were retrospectively 
evaluated. All patients signed the informed consent 
form for genetic testing routinely. 
PCR-RFLP test was performed in 324 postnatal cases 
(180 males, 144 females), and 77 prenatal samples. The 
MLPA test, which has been available since 2013 in our 
lab, was performed in 59 cases (44 parents of affected 
child, 15 SMA patients). The ages of cases changed 
between 5 months and 63 yr. 
PCR-restriction fragment length polymorphism 
(RFLP)
Genomic DNA was extracted from peripheral blood 
samples of suspected individuals, or from a chorionic 
villus biopsy (CVS), cultured amniocytes of the 
prenatal cases using QIAamp DNA mini kit (Qiagen, 
UK ) according to manufacturer’s protocol.
Homozygous deletions in exons 7 and 8 of the 
SMN1 gene were investigated by PCR-RFLP 
method (5). First, PCR was performed to amplify 
exon 7 and 8 of SMN gene using a forward 5´ - 
Molecular Genetic Analysis of Survival Motor Neuron Gene in 460 Turkish Cases with Suspicious Spinal...
32 Iran J Child Neurol. AUTUMN  2016  Vol 10 No 4
Molecular Genetic Analysis of Survival Motor Neuron Gene in 460 Turkish Cases with Suspicious Spinal...
was then diagnosed as SMA type IV.
One case (1-yr-old female) had 2 copies of SMN1 gene 
and homozygote deletion of SMN2. Mild hypotonia 
was observed in this case, she could sit at the age of one. 
It was decided to follow-up further SMA findings and 
perform sequencing before diagnosed to have definite 
SMA disease. Remaining 2 cases (1 yr old and 7 yr old) 
had homozygous deletion of SMN1 and 2 copies of 
SMN2 and, clinically diagnosed as SMA I and SMA III 
disease, respectively.  
Discussion
In our study, from totally 401 patient (324 postnatal and 
77 prenatal) suspicious for SMA 177 (44.14 %) cases 
were determined as SMA by PCR-RFLP method, in 
accordance with another (6). From 159 postnatal cases 
with SMA, 81 (50.94 %) cases were determined as a 
SMA type I, 23 (14.46%) cases as a SMA type II, 49 
(30.82%) as SMA type III, and 6 (3.78%) as SMA type 
IV, similar to Godinho et al. (7).
In this study, from 177 patients (159 postnatal and 18 
prenatal cases) diagnosed as a SMA with PCR-RFLP 
method, 88.13% had homozygote deletion of both exon 
7 and 8 of SMN1 gene, while 21 (11.86%) cases had 
homozygote deletion of exon 7 but the presence of exon 
8 of SMN1. The last one indicates the possibility of 
conversion event (8). It means the exon 7 of SMN1 was 
converted to the exon 7 of the SMN2 while the exon 8 
of SMN1 was still un-changed.  The converted gene is 
called as ‘Hybrid SMN gene’ (9). Therefore, in PCR-
RFLP results of these cases, the exon 7 of SMN1 could 
not be detected while the exon 8 of SMN1 was present. 
We found 18 (23.38 %) fetuses with SMN1 gene deletion 
had a history of previous affected child with SMA type 
I or type II, and termination of pregnancy was preferred 
by all families whose fetuses were diagnosed as a SMA. 
The babies with normal prenatal test results were normal 
healthy live-born babies at term and they did not show 
any features of SMA during the 1-yr follow-up period. 
Information about parental consanguinity was available 
in 95 cases with SMA disease. Sixty-five patients out of 
95 (68%), with SMA disease, were offspring of couples 
with consanguineous marriages
MLPA Results
We used MLPA test as a carrier screening test for 
44 parents (22 couples) with a history of child loss 
due to SMA but without available DNA materials of 
aborted or death child and 15 patients who did not show 
enzymatic digestion of SMN2 PCR products in RFLP 
test. Test results showed that 12 couples (54.5%) were 
heterozygous for SMN1 gene deletion and had 2 or 
3 copies of SMN2 gene pointing out a healthy SMA 
carrier.
Eleven of 15 postnatal cases, which were resistant to 
enzymatic digestion, showed homozygous deletion 
of SMN2 gene and 1 or 2 copies of SMN1 gene with 
MLPA test. 
In one of the cases (10 yr old boy) with very mild 
SMA symptoms, MLPA test for SMA revealed a 
homozygous deletion of SMN1 and 3 copy of SMN2 
gene. Segregation analysis showed that mother had 1 
copy of SMN1 and 2 copies of SMN2 gene, father had 
the same genotype as his son with homozygous deletion 
of SMN1 and 3 copies of SMN2 gene. The father was 
42 yr old and presented with mild SMA symptoms. He 
Table 1. Postnatal SMN1 PCR-RFLP test results.















Exon 7         Exon 8 n =159
8 3 7 0 Del no del 19 12
73 20 42 6* Del del 140 88
del means deletion and no del means without deletion
* Age of cases: 32, 33, 35, 36, 39, 63 years old
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In our study, consanguinity rate was as high as 68% 
similar to the observations in other studies (11, 12). 
Average consanguinity rate is about 23% all over our 
country. As expected, it is much higher among the 
parents of patients with autosomal recessive diseases.
Detection of heterozygous deletion in SMN1 gene 
and screening of SMA carriers in general population 
can been investigated by MLPA. Determination of 
a homozygous deletion in SMN1 gene in a prenatal 
sample is a proof of disease in the fetus where no DNA 
is available from the previous affected child. Rarely 
SMA disease is caused by point mutations in the gene, 
for this reason, clinicians have to keep in mind that if 
the parents are not carrier by deletion analysis and a 
homozygous deletion was not identified in a fetus, we 
may still not exclude the risk of having a child with the 
disease (13, 14).
Among 44 healthy individuals (22 families), carrier 
status was confirmed for 12 (54, 5%) families (both 
mothers and fathers), in accordance with Marijana 
Miskovic et al. on Serbia patients (15).
While the SMN2 copy number relates to severity 
of the disease, the SMN1 and SMN2 copy number 
assessment using MLPA could be useful for the 
correlation of genotype-phenotype in SMA patients 
(16). As an example, in the case of a 42 yr old patient 
with homozygous deletion of SMN1 and 3 copies of 
SMN2 gene with mild SMA symptoms (SMA type 
IV), supporting the previous studies reported greater 
copy number of SMN2 may compensate the absence of 
SMN1 gene and cause to milder SMA phenotypes.
One of our cases (1 yr old female) had 2 copies of SMN1 
gene and homozygote deletion of SMN2. Regarding her 
clinical findings, we consider that whether she has SMA 
or another disease causing hypotonia is controversial.
About 2% of SMA patients showed a de-nova mutation 
in one of the SMN1 alleles resulted from unequal 
crossing over (17, 18).  We performed RFLP analysis 
in most of the patients (324 postnatal and 77 prenatal 
cases). RFLP analysis is not an appropriate test to 
determine the carriers. Therefore, we could not know 
the percentages of patients having de-nova mutations. 
Among 59 cases performed for MLPA test, we did not 
observe any case with de-novo mutations. For more 
accurate genetic counseling, in SMA families, carrier 
from 77 prenatal samples. This is compatible with the 
simple autosomal recessive Mendelian inheritance. 
Ogino et al. reported 14 (14%) samples out of 103 
prenatal samples with SMN1 gene deletion.  The reason 
for their lower frequency of deletion positive fetuses was 
that they performed prenatal test for both carrier parents 
with new partners whose genetic status was unknown, 
and parents with previous affected children without 
screening of SMN gene deletions. Early miscarriages of 
the fetuses with lethal mutations might have contributed 
to the lower frequency of positive results (10). We may 
say that SMA in the fetus does not usually lead to early 
miscarriages. 
As shown in the Table 2, the annual percent of patients 
diagnosed with SMA among postnatal suspicious 
cases, referred to molecular genetics laboratory for 
SMA genetic testing using PCR-RFLP method, was 
decreased gradually from 90.62% in 2003 to 20.83% in 
2014. Since molecular tests have become cheaper and 
more widely available, clinicians have increasingly used 
them in the differential diagnosis of muscular atrophies.
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Table 2. The annual percentage of patients diagnosed 
with SMN1 deletion using PCR-RFLP method among 
suspicious postnatal cases referred to medical genetics 
laboratory for SMN1 genetic testing.
YEAR PATIENT SMA PERCENTAGE 
2003 32 29 90.62
2004 19 17 89.47
2005 18 12 66.66
2006 27 14 51.84
2007 27 15 55.5
2008 16 8 50
2009 21 10 47.61
2010 30 11 36.66
2011 42 19 45.23
2012 29 10 34.48
2013 39 9 23.07
2014 24 5 20.83
TOTAL 324 159 49.07
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muscular atrophy and progressive myoclonic epilepsy: 
one case report and characteristics of the epileptic 
syndrome. Seizure 2004;13:582-6.
4. Wirth B. An update of the mutation spectrum of the 
survival motor neuron gene (SMN1) in autosomal 
recessive spinal muscular atrophy (SMA). Hum Mutat 
2000;15:228-37.
5. Van der Steege G, Grootscholten PM, Van der Vlies P, 
Draaijers TG, Osinga J, Cobben JM, et al. PCR-based 
DNA test to confirm clinical diagnosis of autosomal 
recessive spinal muscular atrophy. Lancet 1995;345:985-
6.
6. Rekik I, Boukhris A, Ketata S, Amri M, Essid N, Feki 
I, et al. Deletion analysis of SMN and NAIP genes in 
Tunisian patients with spinal muscular atrophy. Ann 
Indian Acad Neurol 2013;16:57-61.
7. de Souza Godinho FM, Bock H, Gheno TC, Saraiva-
Pereira ML. Molecular Analysis of Spinal Muscular 
Atrophy: A genotyping protocol based on TaqMan real-
time PCR. Genet Mol Biol 2012;35:955-9.
8. Burghes AH. When deletion is not a deletion? When it is 
converted? Am J Hum Genet 1997;61:9-15.
9. Kubo Y, Nishio H, Saito K. A new method for SMN1 
and hybrid SMN gene analysis 
1. in spinal muscular atrophy using long-range PCR 
followed by sequencing. J Hum
2. Genet 2015;60:233-9.
10. Ogino S, Leonard DG, Rennert H, Wilson RB. Spinal 
Muscular Atrophy Genetic Testing Experience at an 
Academic Medical Center. J Mol Diagn 2002;4:53-8.
11. Baumbach-Reardon L, Sacharow S, Ahearn ME. Spinal 
Muscular Atrophy, X-Linked Infantile. Gene Review 
1993.
12. Khaniani MS, Derakhshan SM, Abasalizadeh S. Prenatal 
diagnosis of spinal muscular atrophy: clinical experience 
and molecular genetics of SMN gene analysis in 36 
cases. J Prenat Med 2013;7:32-4.
13. Lin SP, Chang JG, Jong YJ, Yang TY, Tsai CH, Wang 
NM, et al. Prenatal prediction of spinal muscular atrophy 
in Chinese. Prenat Diagn 1999;19:657-61.
14. Cobben JM, Scheffer H, De visser M, Van der Steege G, 
Verhey JB, Osigna J, et al. Prenatal prediction of spinal 
muscular atrophy. Experience with linkage studies and 
testing with MLPA and sequencing to find the point 
mutations should be performed, when they are available.
In conclusion, a simple, quick and an inexpensive 
PCR-RFLP analysis used as a reliable test for diagnosis 
of deletions in SMN1 gene in most laboratories, is not 
valid for carrier screening. For career screening of 
SMA, MLPA analysis should be used. Furthermore, 
sometimes SMN2 PCR products cannot been digested 
in RFLP tests because of low PCR amplification or 
homozygote deletion of SMN2 gene and leading to false 
negative test results, in this cases MLPA is a reliable 
test for diagnosis of SMA. For all these reasons and for 
SMA carrier screening, MLPA analysis should be used 
as a complementary test with PCR-RFLP.
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